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Clinical Application of Basic ScienceMacrophage heterogeneity in liver injury and ﬁbrosis
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University Hospital Aachen, Department of Medicine III, Pauwelsstrasse 30, 52074 Aachen, GermanySummary to develop novel macrophage subset-targeted therapies for liverHepatic macrophages are central in the pathogenesis of chronic
liver injury and have been proposed as potential targets in com-
batting ﬁbrosis. Recent experimental studies in animal models
revealed that hepatic macrophages are a remarkably heteroge-
neous population of immune cells that fulﬁll diverse functions
in homeostasis, disease progression, and regression from injury.
These range from clearance of pathogens or cellular debris and
maintenance of immunological tolerance in steady state condi-
tions; central roles in initiating and perpetuating inﬂammation
in response to injury; promoting liver ﬁbrosis via activating hepa-
tic stellate cells in chronic liver damage; and, ﬁnally, resolution of
inﬂammation and ﬁbrosis by degradation of extracellular matrix
and release of anti-inﬂammatory cytokines. Cellular heterogene-
ity in the liver is partly explained by the origin of macrophages.
Hepaticmacrophages can either arise from circulatingmonocytes,
which are recruited to the injured liver via chemokine signals, or
from self-renewing embryo-derived local macrophages, termed
Kupffer cells. Kupffer cells appear essential for sensing tissue
injury and initiating inﬂammatory responses, while inﬁltrating
Ly-6C+ monocyte-derived macrophages are linked to chronic
inﬂammation and ﬁbrogenesis. In addition, proliferation of local
or recruitedmacrophages may possibly further contribute to their
accumulation in injured liver. During ﬁbrosis regression, mono-
cyte-derived cells differentiate into Ly-6C (Ly6C, Gr1) low
expressing ‘restorative’ macrophages and promote resolution
from injury. Understanding the mechanisms that regulate hepatic
macrophage heterogeneity, either by monocyte subset recruit-
ment, by promoting restorative macrophage polarization or by
impacting distinctive macrophage effector functions, may helpJournal of Hepatology 20
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Hepatic macrophages hold a central position in the pathogenesis
of chronic liver injury and have been proposed as potential targets
in combatting ﬁbrosis [1]. The ambivalence of macrophage activ-
ity in experimental liver damage and the identiﬁcation of func-
tionally opposing macrophage subsets, though, have impeded
the development of macrophage-based interventional strategies
so far. In congruence with the fact that liver ﬁbrosis is not an uni-
directional irreversible process, hepatic macrophages can actually
exert dual functions in the context of experimental liver ﬁbrosis
by either promoting or abrogating the excessive deposition of
extracellular matrix [2]. Intriguing questions have arisen from this
ﬁnding, and current research focuses on unscrambling mecha-
nisms of functional diversity underlying the opposing tasks of
hepatic macrophages throughout the evolution of liver scarring.
Important aspects include the origin of the macrophage subsets
(derived from circulating monocyte precursors vs. resident Kupf-
fer cells), their differentiation (oftentimes classiﬁed as M1 vs.
M2 polarization) as well as their effector functions in the context
of liver diseases.Macrophage heterogeneity
Macrophage heterogeneity is expressed by a high diversity in
cytokines released, cell surface markers and transcriptional pro-
ﬁles. In order to accommodate for the broad spectrum of macro-
phage function and phenotypes, these cells have been classiﬁed
either into ‘pro-inﬂammatory’ M1 or ‘immunoregulatory’ M2
macrophages, though this simple dichotomous nomenclature
does not fully reﬂect the complex biology of macrophage subsets
[3]. Consequently, M2 macrophages are now further categorized
into various subtypes that pursue wound healing or anti-inﬂam-
mation but may also promote inﬂammation in some circum-
stances. M1 macrophages are intimately linked to Th1 primed
CD4 T-cells, whereas M2 macrophages reciprocally engage with
Th2 CD4 T-cells. M1 macrophages are typically induced by IL-
12, IFN-c, and LPS in response to acute deleterious incidents,
whereas M2 macrophages are controlled by IL-4 and IL-13 [4].14 vol. 60 j 1090–1096
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Key effector functions of ‘classical macrophages’ (M1) are bacte-
rial clearance, antiviral activity and release of pro-inﬂammatory
cytokines (such as TNF, IL-1b, IL-12, reactive oxygen species),
while ‘alternatively activated macrophages’ (M2) promote
defense against parasitic infections, are involved in tissue remod-
eling and secrete immune-modulatory mediators (such as IL-10,
TGF-b, IL-4, IL-13) [3]. However, in disease conditions that are
not exclusively skewed towards one end of the spectrum such
as acute bacterial peritonitis (M1) or chronic helminth (M2)
infection, it is very difﬁcult to assign tissue macrophages to clas-
sical or alternative activation. In fact, liver macrophages appear to
express markers of M1 and M2 differentiation simultaneously [5],
indicating that this dichotomous concept cannot be entirely
applied to hepatic diseases. Rodent models of injury rather indi-
cate that the function of hepatic macrophage subsets in the con-
text of liver diseases largely depends on their origin [6].
Therefore, we propose to distinguish between resident hepatic
macrophages, termed Kupffer cells, and inﬁltrating bone mar-
row-derived macrophages, originating from circulating mono-
cytes, to characterize macrophage heterogeneity in the liver.Resident hepatic macrophages in health and disease
Owing to its unique vascular supply the liver is constantly
exposed to high concentrations of blood-borne food antigens
and bacterial constituents derived from the commensal intestinal
ﬂora (Fig. 1). Therefore, highly orchestrated innate immune
mechanisms in the liver are required to prevent the instigation
of inﬂammatory responses towards those harmless substrates.
Due to their potent phagocytic capacity, high density of surface
scavenger and pattern recognition receptors as well as the ability
to release numerous mediators that govern the local immunolog-
ical milieu, resident hepatic macrophages meet the prerequisite
to balance this incessant immunogenic stimulus and promote tol-
erance (e.g., dampening of T cell activation) [6]. Actually, under
steady state conditions the liver harbors the most abundant pool
of macrophages in the whole body. It has long been debated
whether circulating monocytes contribute to the Kupffer cell
pool. Data from bone marrow and liver transplanted mice dem-
onstrated that monocytes in principle can give rise to functional
hepatic macrophages without overt inﬂammatory stimuli to the
liver [7]. However, already in 1997, Naito and coworkers pro-
vided experimental data indicating that Kupffer cells almost
exclusively originate from fetal yolk sac precursors and self-
renew throughout adult life in homeostasis, depending on prolif-
erative signals via M-CSF [8]. These ﬁndings could be recently
recapitulated using sophisticated cell tracking techniques. These
experiments revealed that Kupffer cells delineate from local pre-
cursors and constantly renew themselves dependent on the
growth factors GM-CSF and M-CSF [9].
During inﬂammation the hepatic macrophage pool is even
expanded, and a startling scientiﬁc debate is ongoing regarding
the origin and underlying mechanisms of macrophage enrich-
ment. In the early phase after a hazardous incident, sessile hepa-
tic macrophages rapidly secrete pro-inﬂammatory cytokines and
chemokines such as IL-1b, TNF, CCL2, and CCL5, resulting in the
paracrine activation of protective or apoptotic signaling path-
ways of hepatocytes and the recruitment of additional immune
cells that booster hepatic injury [10] (Fig. 1). In addition, not only
inﬂammatory stimuli, but also metabolic signals may modulateJournal of Hepatology 2014the activation of hepatic macrophages, as evidenced for the over-
load of lipids and certain cholesterol derivatives in Kupffer cells
in models of fatty liver disease and steatohepatitis [11,12].
The central location of Kupffer cells in the sinusoids also
allows intimate interactions with other non-parenchymal hepatic
cell populations (Fig. 1). On the one hand, hepatic macrophages
interact with other immune cells; for instance, they secrete the
chemokine CXCL16 that attracts NKT cells, which in turn can acti-
vate pro-inﬂammatory signals in macrophages [13]. On the other
hand, there is clear evidence from in vitro and in vivo studies that
Kupffer cells can activate hepatic stellate cells (HSC) to transdif-
ferentiate into myoﬁbroblasts, the major collagen-producing cell
type in hepatic ﬁbrosis [14,15]. Kupffer cells activate HSC via par-
acrine mechanisms, likely involving the potent proﬁbrotic and
mitogenic cytokines TGF-b and PDGF (Fig. 1) [15]. These proﬁb-
rotic functions of Kupffer cells during chronic hepatic injury
remain functionally relevant, even if the inﬁltration of additional
inﬂammatory monocytes is blocked via pharmacological inhibi-
tion of the chemokine CCL2 [16].
Moreover, hepatic macrophages can express several matrix
metalloproteinases (MMP), including MMP-9, MMP-12, and
MMP-13, that are involved in matrix degradation and thereby
favor resolution of liver injury and ﬁbrosis [17,18]. Although it
appears plausible that Kupffer cells, which have tolerogenic and
immune-suppressive functions in homeostasis, may undergo a
phenotypic switch and promote tissue remodeling, experimental
evidence assigning such antiﬁbrotic functions to resident macro-
phages are currently lacking (Fig. 2).
The opposing effects of macrophage activation in homeostasis
and inﬂammation indicate the versatile nature of Kupffer cells
that could possibly rest on heterogeneous subsets that merge into
the term ‘hepatic macrophage’ or on the plasticity of the cells that
may adopt various phenotypes according to the hepatic microen-
vironment. Due to their high phagocytic and endo(pino)cytic
capacity, local Kupffer cells can be relatively easy targeted by bio-
functionalized nanoparticles intended to inﬂuence macrophage
polarization as well as by carrier tools designed to deliver drugs
directly to Kupffer cells (Table 1) [19,20]. In order to translate
such concepts into clinical applications, however, the precise
contribution of local macrophages to liver injury, ﬁbrosis, and
resolution in relation to invading monocyte-derived macro-
phages needs to be fully dissected.Monocytes as precursors of hepatic macrophages
While circulating monocytes are likely dispensable for replenish-
ing the hepatic macrophage pool in homeostasis, hepatic meta-
bolic or toxic damage results in the massive inﬁltration of
monocyte-derived macrophages into the liver (Fig. 1). Murine
models revealed that ‘inﬂammatory’ Ly-6Chi expressing mono-
cytes accumulate in injured liver, dependent on the chemokine
– receptor interactions CCL2/CCR2 or CCL1/CCR8 [21–24]. One
of the major sources of CCL2 are HSCs, which are activated
through TLR4 ligands and thereby guide monocyte recruitment
[25]. Freshly inﬁltrating (monocyte-derived) macrophages are
characterized as CD11b+ F4/80+ cells by FACS in mice, whereas
matured monocyte-derived and resident Kupffer cells are
CD11blo F4/80hi [20,23]. Targeted deletion of macrophages in
CD11b-diphteria toxin receptor (DTR) transgenic mice amelio-
rates liver ﬁbrosis similar to the abrogation of chemokine
pathways that control monocyte inﬂux [2,23,26,27], suggestingvol. 60 j 1090–1096 1091
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Fig. 1. Hepatic macrophage heterogeneity during initiation and progression of chronic liver injury and ﬁbrosis (mouse models). In the initial phase of hepatic injury,
epithelial cell damage affecting hepatocytes or cholangiocytes perish and release Danger-Associated-Molecular-Pattern molecules (DAMPs) such as RNA, DNA, or alarmins
(like HMBG-1) that activate resident Kupffer cells (KC), located at the luminal side of the liver sinusoidal endothelium (LSEC). In turn, Kupffer cells secrete pro-inﬂammatory
cytokines like IL-1b and TNF that perpetuate parenchymal damage by inducing apoptosis. Furthermore, increased sinusoidal levels of Pathogen-Associated-Molecular-
Pattern molecules (PAMPs) including lipopolysaccharide (LPS) stimulate Kupffer cells but also hepatic stellate cells (HSC) through Toll-like-Receptor 4 (TLR4) activation that
leads to TGF-b sensitization and secretion of CCL2 by HSC as well as potent activation of KCs. Increased levels of CCL2 promote chemotaxis of bone marrow-derived
‘classical’ Ly-6Chi monocytes that enter the liver, where they develop into inﬁltrating Ly-6C+ macrophages exhibiting a pro-inﬂammatory phenotype. Freshly inﬁltrating
hepatic macrophages booster the progression of chronic liver injury and ﬁbrosis through TGF-b/PDGF-mediated HSC transdifferentiation and proliferation. The contribution
of locally proliferating hepatic macrophages to the initiation and progression of chronic liver injury remains elusive. Overall, these mechanisms lead to the accumulation of
collagen forming scar tissue.
Clinical Application of Basic Sciencethat inﬁltrating monocytes exert major proﬁbrotic functions in
ﬁbrosis progression (Fig. 1). Apart from directly stimulating
matrix-secreting HSC, hepatic macrophages may aggravate scar-
ring by promoting HSC survival via IL-1 and TNF induced NF-jB
activation [15]. Interestingly, the proﬁbrogenic effect of inﬁltrat-
ing monocytes in mouse models depends on the underlying
genetic background. Balb/c mice, in which Th2 immune
responses inherently prevail, are more protected from liver
damage and ensuing ﬁbrosis by the disruption of monocyte inﬁl-
tration than Th1-dominated C57Bl/6 mice, indicating that M11092 Journal of Hepatology 2014and M2 polarization might directly inﬂuence the outcome in
chronic hepatic injury [21]. Another important factor determin-
ing the fate of invading monocytes as to the extent of liver dam-
age is the fractalkine receptor CX3CR1, predominantly present on
non-classical Ly-6Clo monocytes, in the absence of which mono-
cyte-derived macrophages differentiate into detrimental iNOS
and TNF-a producing effector cells [28].
As outlined above, macrophages can also enhance ﬁbrosis reso-
lution in a phase-dependent fashion through the secretion ofmatrix
metalloproteinases (Fig. 2) [17,29]. Hence, not only the interferencevol. 60 j 1090–1096
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Fig. 2. Hepatic macrophage heterogeneity during regression of chronic liver injury and ﬁbrosis (mouse models). In the course of chronic liver injury, Ly-6Chi
macrophages can adopt a restorative phenotype characterized by Ly-6Clo expression and the capacity to degrade excessive extracellular matrix proteins via
metalloproteinases (MMP-9,-12,-13) and to induce HSC apoptosis. CX3CL1 (fractalkine) promotes survival of intrahepatic macrophages and may induce maturation of
Ly-6C+ cells. Engulfment of cell fragments derived from apoptotic cells can further promote restorative features of hepatic macrophages. The function of freshly recruited
Ly-6Clo monocytes for the regenerating liver remains to be established. Overall, these mechanisms lead to the degradation of extracellular matrix during resolution of liver
ﬁbrosis.
JOURNAL OF HEPATOLOGYwith the recruitment of ‘proﬁbrogenic’ monocytes was tested in
experimental settings, but also the cell transfer of ‘ﬁbrolytic’ mono-
cytes/macrophages. As such, the delivery of syngeneicmaturemac-
rophages, but not immature (precursor) monocytes, into CCl4-
treatedmice reduced liver scarringbyattractingother immunecells
resulting in enhanced levels of the antiﬁbrotic cytokine IL-10 and
increasedMMP-9 and -13 activation, accompanied by the elevation
of the local growth factor levels IGF-1, VEGF, andCSF-1 [30]. The fact
that only terminally differentiated macrophages bear the potential
to facilitate ﬁbrosis regression in contrast to their progenitors sug-
gests that hepatic macrophage function varies according to disease
kinetics and environmental cues.
Following this concept, early inﬁltrating monocytes elicit
organ impairment, whereas after local differentiation intoJournal of Hepatology 2014resident macrophages, these cells can gain the ability to restore
liver integrity (Fig. 2). Recently, ‘restorative macrophages’, char-
acterized by Ly-6Clo expression in mice, have been identiﬁed that
are competent in resolving ﬁbrosis and accumulated in the
restorative phase after tissue damage [5]. These Ly-6Clo macro-
phages directly delineate from inﬁltrating Ly-6Chi monocytes/
macrophages [5], thus undergo a functional switch in the course
of liver injury due to mechanisms that warrant further elucida-
tion. Of note, transcriptome analysis revealed that these Ly-6Clo
hepatic macrophages display a proﬁle that cannot be classiﬁed
according to the M1/M2 nomenclature. A striking feature of those
restorative macrophages is that they are postphagocytic, because
injection of liposomes boosted the degradation of extracellular
matrix [5]. Interestingly, even after cessation of liver injury, avol. 60 j 1090–1096 1093
Table 1. Conceivable therapeutic applications targeting hepatic macrophage heterogeneity (derived from experimental models of chronic liver injury).
Target
Inhibition of (Ly-6C+) inflammatory
Possible approach (selected from experimental models)
• Pharmacological antagonism of CCL2 (MCP-1) small using inhibitory RNA molecules (so-
called Spiegelmers) [16]
• Pharmaceutical inhibition of CCR2 [24]
• Intestinal decontamination by antibiotics, leading to lower hepatic levels of LPS and reduced 
monocyte recruitment [25]
Neutralization of TNF and IL-1 to promote apoptosis of activated hepatic myofibroblasts [15]
Biofunctionalized nanoparticles influencing hepatic macrophage polarization [20]
Inhibition of inflammatory monocyte influx during the regression of fibrosis [31] 
cytokines released by hepatic 
Counteraction of pro-inflammatory
macrophages
• 
Switching/modulating hepatic 
macrophage polarization (M1-M2)
• 
• Delivery of “polarizing” drugs (e.g., dexamethasone) to hepatic macrophages [19]
Augmentation of restorative hepatic 
macrophages
• Administration of CX3CL1 to induce a protective hepatic macrophage phenotype [28] 
• Application of IL-4 to force local proliferation of tissue-remodeling macrophages [33]
• Autologous cell transfer of in vitro matured and polarized macrophages [30]
• 
monocyte influx
Clinical Application of Basic Sciencesustained inﬂux of Ly-6Chi macrophages can be observed, that
dampens spontaneous ﬁbrosis regression by producing pro-
inﬂammatory cytokines such as TNF. Blocking the CCL2-depen-
dent inﬂux in the phase of ﬁbrosis resolution therefore even
enhances clearance of scar ﬁbers [31]. These ﬁndings substantiate
the theory that freshly inﬁltrating macrophages worsen liver
injury, whereas restoration is elicited by locally matured mono-
cyte-derived macrophages.Proliferation of hepatic macrophages in liver injury?
Fate mapping studies revealed that Kupffer cells originate pre-
natally from either the yolk sac or local precursors and maintain
themselves by self-renewal through proliferation [8,9]. In line,
the absence of the transcription factor Myb1, which is critical
for hematopoietic stems cells, does not affect the presence of
Kupffer cells, indicating that myeloid precursor cells are dis-
pensable for the population of hepatic macrophages in homeo-
stasis [32]. However, there is increasing evidence that even
during certain types of inﬂammation, accumulation of macro-
phages derives from the division of resident cells. In Th2-dom-
inated helminth infection alternatively activated pleural
macrophages proliferate in response to IL-4 beyond physiologi-
cal borders set by the availability of CSF-1 [33,34]. Importantly,
IL-4 also drives replication of Kupffer cells, denoting that this
phenomenon may hold true for the liver as well [33]. Of note,
alternatively activated arginase-expressing macrophages are
capable of constraining liver ﬁbrosis in an archetypical Th2
inﬂammation model and it is conceivable that they also delin-
eate from local precursors [35]. However, more detailed studies
are necessary to assess the contribution of in situ proliferating
macrophages for expanding the macrophage pool during infec-
tions and sterile liver inﬂammation. Moreover, it is currently
unclear whether only resident Kupffer cells or also monocyte-
derived macrophages are capable of proliferating upon inﬂam-
mation (Fig. 1). In conditions of atherosclerosis or peritonitis,
inﬁltrated monocyte-derived as well as tissue resident macro-
phages locally proliferated in response to inﬂammatory stimuli
[36,37]. In case of progressing liver injury, the contribution of
local macrophage proliferation in the liver remains to be
determined.1094 Journal of Hepatology 2014Heterogeneity of human hepatic macrophages and translation
into clinical applications
A major obstacle for the development of novel therapies for liver
ﬁbrosis targeting macrophages is the signiﬁcant paucity of func-
tional data in man. Distinct macrophage populations can also be
found in human liver, including ‘classical’ CD14++CD16 and
‘non-classical’ CD14+CD16+ monocytes/macrophages as well as
CD16++ cells that include atypical macrophages and dendritic
cells [38]. The progression of chronic liver diseases from hepatitis
to ﬁbrosis and eventually to cirrhosis is closely associated with an
enrichment of ‘non-classical’ CD14+CD16+ monocyte-derived
macrophages in the liver of patients with various disease etiolo-
gies [39]. The accumulation of these cells is likely based on two
mechanisms: facilitated recruitment across inﬂamed sinusoidal
endothelium and local transdifferentiation from CD14++CD16
precursor cells [38], reminiscent of the maturation of murine
Ly-6C+ to Ly-6Clo macrophages in experimental rodent liver
injury [5,23].
Circulating human CD14+CD16+ monocytes share phenotypic
features with murine Ly-6Clo monocytes [40], but intrahepatic
human CD14+CD16+ macrophages are strikingly similar to mouse
inﬂammatory monocyte-derived macrophages with respect to
functional aspects, as these cells release proinﬂammatory as well
as ﬁbrogenic mediators [38]. On the other hand, human intrahe-
patic CD14+CD16+ macrophages possess a high phagocytic activ-
ity, which has been identiﬁed as a feature of ‘restorative’ (Ly-6Clo)
hepatic macrophages in mice [5]. These partly overlapping and
partly opposing features of human and mouse macrophage sub-
sets require further translational research. Very likely, our cur-
rent deﬁnitions of the distinct hepatic macrophages still
comprise mixed populations of functionally distinct cell subsets,
whose differentiating marker and gene expression proﬁles
remain to be deciphered.
Another impediment in translating ﬁndings from mouse mod-
els to human disease is the wide spectrum of chronic liver disor-
ders in humans. It is very likely that the functionality of hepatic
macrophage subsets is inﬂuenced by the nature of the underlying
liver disease (e.g., lipid overload in fatty liver disease; antigen-
speciﬁc responses in autoimmune hepatitis; impact of bile acids
in cholangiopathies). Current studies have focused on the stage
of disease progression (ﬁbrosis, cirrhosis) rather than the naturevol. 60 j 1090–1096
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of the underlying injury [38,39]. Hence, further translational
research is warranted to address disease-speciﬁc characteristics
of hepatic monocyte and macrophage heterogeneity.
Nevertheless, many of the pathways characterized in mice for
monocyte recruitment and macrophage effects are also strongly
regulated in patients with liver diseases, suggesting well con-
served mechanisms of macrophage activation across species
[41]. Such pathways may possibly serve as novel targets for ther-
apeutic approaches (for a summary of selected potential targets,
see Table 1). For instance, activation of the CCL2-CCR2 axis
is associated with monocyte inﬁltration in patients with
chronic liver diseases and parallels ﬁbrogenesis [39,42]. Also,
CD14+CD16+ monocyte-derived macrophages are capable of acti-
vating human stellate cells in vitro, partially dependent on TGF-b
release [39]. The way human hepatic macrophage subsets shape
the outcome of chronic liver disease is still unresolved and needs
to be clariﬁed before new therapeutic agents aiming at macro-
phage inﬁltration or polarization can enter clinical trials.
Key Points
• Macrophages exert critical functions in liver 
homeostasis, in the initiation of inflammation 
in response to hepatic injury and induction of 
fibrogenesis, but also in resolution of inflammation and 
fibrosis
• Animal models from experimental liver injury revealed 
a remarkable heterogeneity of hepatic macrophages 
with diverse functions
• Important aspects of hepatic macrophage 
heterogeneity include the origin of the macrophage 
subsets (derived from circulating monocyte precursors 
vs. resident Kupffer cells), their differentiation (often 
termed M1 vs. M2 polarization) as well as their effector 
functions in the context of liver diseases
• Macrophage subpopulations with distinct functional 
properties have also been identified in human livers 
from patients with chronic liver diseases and fibrosis
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